Detecting residual host cell DNA with Droplet Digital PCR technology

Cell & Gene Therapy Insights 2022; 8(3), 443


Published: 4 April 2022
Mark White

Watch the video or read the poster to find out:

  • How ddPCR technology may be leveraged for the effective removal of residual host cell DNA from cell and gene therapy products, thus enhancing product and patient safety
  • What specific benefits and advantages ddPCR technology can offer compared to alternative tools for residual host cell DNA detection, sizing, and quantification

Mark White is the Associate Director of Biopharma Product Marketing at Bio-Rad. He has played a key role in the development of multiple core technology capabilities and assays alongside a multidisciplinary team of biologists and engineers at Bio-Rad and previously at Berkeley Lights Inc.. Mark obtained his Ph.D. in Biomedical Sciences at the University of California, San Francisco.